{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:53:13Z","timestamp":1792666393320,"version":"4.5.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To assess the safety of the respiratory syncytial virus prefusion F protein (RSVpreF) vaccine in pregnant women during the 2024\u20132025 French immunization campaign, with a particular focus on the risk of preterm birth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Using the national health care database, which covers almost 99% of the population in France, we included all women who gave birth after 22 weeks of gestation between September 16 and December 31, 2024. Women vaccinated with RSVpreF were matched 1:1 with unvaccinated women on the basis of gestational age at vaccination, maternal age at pregnancy onset, region of residence, week of conception, history of preterm birth, influenza vaccination during the same pregnancy, and multiple pregnancy. Outcomes included preterm birth, delivery within 1 and 3 weeks after vaccination, stillbirth, small-for-gestational-age (SGA) birth weight, cesarean delivery, hemorrhage, preeclampsia, and major cardiovascular events, including maternal death. Time-to-event analyses were conducted with Poisson regression models with robust variance to estimate weighted incidence rate ratios (IRRs) and their 95% CIs for each outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Among the 29,032 women vaccinated during the study period, 24,891 (85.7%) were successfully matched to 24,891 unvaccinated women in a control group. In the matched cohort, the mean\u00b1SD maternal age was 30.9\u00b15.0 years, 3.2% had a history of preterm birth, 0.6% had multiple pregnancies, and 21.8% had received influenza vaccination. No significant increase in the risk of the following outcomes was observed: preterm birth (weighted IRR 0.97, 95% CI, 0.89\u20131.06), delivery within 1 week (weighted IRR 0.81, 95% CI, 0.72\u20130.90) or within 3 weeks (weighted IRR 0.97, 95% CI, 0.93\u20131.00), stillbirth (weighted IRR 0.77, 95% CI, 0.45\u20131.32), cesarean delivery (weighted IRR 1.00, 95% CI, 0.96\u20131.03), SGA birth weight (weighted IRR 1.01, 95% CI, 0.96\u20131.07), postpartum hemorrhage (weighted IRR 1.03, 95% CI, 0.97\u20131.10), preeclampsia (weighted IRR 1.02, 95% CI, 0.85\u20131.22), or major adverse cardiovascular event (weighted IRR 0.60, 95% CI, 0.26\u20131.40) outcomes. Among women vaccinated at or before 32 weeks of gestation, no significant increase in the risk of preterm birth was observed (weighted IRR 1.13, 95% CI, 0.98\u20131.31).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>This large observational study found no major safety concerns associated with RSVpreF vaccination during pregnancy. Further research, including international comparisons and evaluations of effectiveness relative to monoclonal antibodies against RSV, will be needed to fully characterize the benefit\u2013risk balance of RSVpreF. Ongoing surveillance remains essential, particularly to monitor rare adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006121","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T22:00:22Z","timestamp":1763071222000},"page":"118-126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Maternal and Neonatal Outcomes After Respiratory Syncytial Virus Prefusion F Protein Vaccination During Pregnancy"],"prefix":"10.1097","volume":"147","author":[{"given":"Am\u00e9lie","family":"Gabet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Jo\u00eblle","family":"Jabagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epiphane","family":"Kolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Oli\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/AOG.0000000000005817","article-title":"Preterm birth frequency and associated outcomes from the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal trial of the bivalent respiratory syncytial virus prefusion F protein vaccine","volume":"145","author":"Madhi","year":"2025","journal-title":"Obstet Gynecol"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2305478","article-title":"RSV prefusion F protein-based maternal vaccine\u2014preterm birth and other outcomes","volume":"390","author":"Dieussaert","year":"2024","journal-title":"N Engl J Med"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12879-020-4824-3","article-title":"Safety and effectiveness of acellular pertussis vaccination during pregnancy: a systematic review","volume":"20","author":"Vygen-Bonnet","year":"2020","journal-title":"BMC Infect Dis"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1016\/j.vaccine.2017.04.074","article-title":"No association between influenza vaccination during pregnancy and adverse birth outcomes","volume":"35","author":"Zerbo","year":"2017","journal-title":"Vaccine"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/21645515.2018.1540807","article-title":"The safety of inactivated influenza vaccines in pregnancy for birth outcomes: a systematic review","volume":"15","author":"Giles","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1038\/s41467-022-30052-w","article-title":"Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy","volume":"13","author":"Prasad","year":"2022","journal-title":"Nat Commun"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"e069741","DOI":"10.1136\/bmj-2021-069741","article-title":"Covid-19 vaccination in pregnancy","volume":"378","author":"Badell","year":"2022","journal-title":"BMJ"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"e2434","DOI":"10.1002\/rmv.2434","article-title":"Effects of COVID-19 vaccination during pregnancy on SARS-CoV-2 infection and maternal and neonatal outcomes: a systematic review and meta-analysis","volume":"33","author":"Rahmati","year":"2023","journal-title":"Rev Med Virol"},{"issue":"suppl 4","key":"R11-20260930","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the Syst\u00e8me National D'information Interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Pub"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"e1004576","DOI":"10.1371\/journal.pmed.1004576","article-title":"First-trimester exposure to macrolides and risk of major congenital malformations compared with amoxicillin: a French nationwide cohort study","volume":"22","author":"Tran","year":"2025","journal-title":"PLoS Med"},{"key":"R13-20260930","doi-asserted-by":"crossref","first-page":"127070","DOI":"10.1016\/j.vaccine.2025.127070","article-title":"COVID-19 vaccination rates among pregnant women in France: a nationwide cohort study","volume":"53","author":"Bernard","year":"2025","journal-title":"Vaccine"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pds.4556","article-title":"Development of an algorithm to identify pregnancy episodes and related outcomes in health care claims databases: an application to antiepileptic drug use in 4.9 million pregnant women in France","volume":"27","author":"Bloti\u00e8re","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R15-20260930","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jama.2021.11035","article-title":"Association between BNT162b2 vaccination and incidence of SARS-CoV-2 infection in pregnant women","volume":"326","author":"Goldshtein","year":"2021","journal-title":"JAMA"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cmi.2025.03.014","article-title":"Safety of pertussis vaccination in pregnancy and effectiveness in infants: a Danish national cohort study 2019-2023","volume":"31","author":"Kildegaard","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"126506","DOI":"10.1016\/j.vaccine.2024.126506","article-title":"The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination","volume":"44","author":"Choi","year":"2025","journal-title":"Vaccine"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)60932-6","article-title":"International standards for newborn weight, length, and head circumference by gestational age and sex: the newborn cross-sectional study of the INTERGROWTH-21st project","volume":"384","author":"Villar","year":"2014","journal-title":"Lancet"},{"key":"R21-20260930","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/MLR.0000000000001745","article-title":"The economic burden of disease in France from the National Health Insurance Perspective: the healthcare expenditures and conditions mapping used to prepare the French Social Security Funding Act and the Public Health Act","volume":"60","author":"Rachas","year":"2022","journal-title":"Med Care"},{"key":"R23-20260930","article-title":"Investigation of maternal outcomes following respiratory syncytial virus vaccination in the third trimester: insights from a real-world U.S. electronic health records database","author":"Jin Hsieh","year":"2025","journal-title":"Am J Obstet Gynecol."},{"key":"R24-20260930","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, safety, and immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal respiratory syncytial virus prefusion F protein vaccine trial","volume":"145","author":"Sim\u00f5es","year":"2025","journal-title":"Obstet Gynecol"},{"key":"R25-20260930","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R26-20260930","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00431-019-03563-w","article-title":"Vaccination during pregnancy: current and possible future recommendations","volume":"179","author":"Maertens","year":"2020","journal-title":"Eur J Pediatr"},{"key":"R27-20260930","doi-asserted-by":"crossref","first-page":"127497","DOI":"10.1016\/j.vaccine.2025.127497","article-title":"Safety monitoring of Pfizer's respiratory syncytial virus vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2023-2024, United States","volume":"62","author":"Moro","year":"2025","journal-title":"Vaccine"},{"key":"R28-20260930","doi-asserted-by":"crossref","first-page":"e087850","DOI":"10.1136\/bmjopen-2024-087850","article-title":"Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System","volume":"15","author":"Alami","year":"2025","journal-title":"BMJ Open"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:00:57Z","timestamp":1790780457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006121"}},"subtitle":["Analysis From the 2024\u20132025 Immunization Campaign in France"],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006121","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"2025-08-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}